Laplace Announces FDA IDE Approval of TRIUMPH Pivotal Trial of Its Transcatheter Tricuspid Valve Replacement System

MINNEAPOLIS, June 29, 2026 /PRNewswire/ — Laplace Interventional today announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) for TRIUMPH, the company's pivotal trial evaluating its Transcatheter Tricuspid Valve Replacement (TTVR) system.…

Read the full release →

News provided by PR Newswire.